- Technology and Data
- Front End Sales and Marketing
- Allergy
- HIV
- Women's Health
- Migraine
- Compounding
- Continuous Glucose Monitoring
- Mental Health Awareness
- Veterinary Pharmacy
- CBD
- Infectious Disease
- Eye Health
- Digestive Health
- Biosimilars
- Influenza
- Shingles
- COPD Management
- Pediatrics
- Generics
- Pain Management
- COVID-19
- Immunization
- Oncology
- Anticoagulants
- Autoimmune Diseases
- Dermatology
- Diabetes
- Respiratory
- Heart Health
- Cardiovascular Clinical Consult
Perrigo continues Clay-Park conversions
In its ongoing effort to bring Clay-Park Labs products under the Perrigo brand, Perrigo recently announced 12 more product conversions. While most product changes will not affect NDC, UPC, and outer case pack dimensions, the company also created new NDCs for two triamcinolone products.
In its ongoing effort to bring Clay-Park Labs products under the Perrigo brand, Perrigo recently announced 12 more product conversions. While most product changes will not affect NDC, UPC, and outer case pack dimensions, the company also created new NDCs for two triamcinolone products. The remaining conversions include: Dctn Ammonium Lactate 12% Crm 2 80 gm; Betamethasone Dprpnt 0.05%, Desonide 0.05%, Econazole Nitrate 1%, Fluticasone Prpnt 0.05%, Gentamicin Sulfate 0.1%, Gentamicin 0.1%, and Permethrin 5%. The entire product line as well as more information can be found at www.perrigo.com.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
